Loading...

VRDN VIRIDIAN THERAPEUTICS INC Other Situations 8-K Filing

VRDN

VRDN

VIRIDIAN THERAPEUTICS INC

(VRDN)

2025 8-K

Show Summary

Summary

Financial Statements

Director Appointment

Stock Sale Agreement

Financial Results

CFO Appointment

Positive Trial Results

Financial Results

Positive Trial Results

Financial Results

Investor Presentation

Annual Meeting Approval

Financial Results

Lease Agreement Amendment

Financial Results

Underwriting Agreement

Departure and Appointment o...

Financial Results

Resignation and Bylaws Adop...

Private Placement and Manag...

Appointment of Director

Management Change

Regulation FD Disclosure

Annual Meeting Approval

Financial Results

Departure of Directors

Regulation FD Disclosure

Financial Results

Appointment of President an...

External Links:

On May 20, 2025, Viridian Therapeutics announced positive long-term durability data from the THRIVE phase 3 clinical trial for their drug veligrotug, which treats active thyroid eye disease.

AI Assistant

VIRIDIAN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.